Therapeutic Asset Ratings
13,155 results matching 1 filter
91,564
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Rituximab
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
SWOG Cancer Research Network
P2
B
(60)
Rituximab
CD4+/CD56+ Hematodermic Neoplasm
St. Jude Children's Research Hospital
P2
B
(60)
Rituximab
Chronic Myelomonocytic Leukemia
Prelude Therapeutics
P2
B
(60)
Rituximab
Fanconi Anemia
Porteus, Matthew, MD
P2
B
(60)
Rituximab
Hematopoietic And Lymphoid System Neoplasm
Indapta Therapeutics, INC.
P2
B
(60)
Rituximab
Plasma Cell Myeloma
Indapta Therapeutics, INC.
P2
B
(60)
Rituximab
Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome
M.D. Anderson Cancer Center
P2
B
(60)
Rituximab
Central Nervous System Non-Hodgkin Lymphoma
The First Affiliated Hospital with Nanjing Medical University
P2
B
(60)
Rivoceranib
Gastroesophageal Junction Adenocarcinoma
Yunpeng Liu
P2
B
(60)
RVU120
Myelodysplastic Syndrome
Ryvu Therapeutics SA
P2
B
(60)
rxc007
Idiopathic Pulmonary Fibrosis
Redx Pharma Ltd
P2
B
(60)
Sacituzumab Tirumotecan
Small Cell Lung Carcinoma
Sichuan University
P2
B
(60)
Sapanisertib
Uterine Corpus Cancer
National Cancer Institute (NCI)
P2
B
(60)
Sapanisertib
Plasma Cell Myeloma
National Cancer Institute (NCI)
P2
B
(60)
Sargramostim
Breast Adenocarcinoma
Mayo Clinic
P2
B
(60)
Saruparib
Small Cell Lung Carcinoma
SWOG Cancer Research Network
P2
B
(60)
Selinexor
B-Cell Non-Hodgkin Lymphoma
Samsung Medical Center
P2
B
(60)
Selinexor
Small Cell Lung Carcinoma
Tianjin Medical University Cancer Institute and Hospital
P2
B
(60)
Selinexor
Extranodal Nasal NK/T Cell Lymphoma
Beijing Tongren Hospital
P2
B
(60)
Selpercatinib
Medullary Thyroid Gland Carcinoma
Eli Lilly and Company
P2
B
(60)
Selpercatinib
Soft Tissue Sarcoma
National Cancer Institute (NCI)
P2
B
(60)
Selumetinib
Female Reproductive Organ Cancer
National Cancer Institute (NCI)
P2
B
(60)
Selumetinib
Metastatic Melanoma
National Cancer Institute (NCI)
P2
B
(60)
Sevasemten
Becker Muscular Dystrophy
Edgewise Therapeutics, Inc.
P2
B
(60)
Shr-A2102
Non-Small Cell Lung Carcinoma
Shanghai Hengrui Pharmaceutical Co., Ltd.
P2
B
(60)
Showing 2151 to 2175 of 13,155 assets
Previous
Page 87 of 527
Next